# Alefacept Mechanism of Action in Psoriasis

> **NCT00150982** · PHASE2 · COMPLETED · sponsor: **University of Medicine and Dentistry of New Jersey** · enrollment: 9 (—)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Mechanism of action of alefacept

## Key facts

- **NCT ID:** NCT00150982
- **Lead sponsor:** University of Medicine and Dentistry of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** —
- **Final completion:** 2005-02
- **Target enrollment:** 9 (—)
- **Last updated:** 2008-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00150982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00150982, "Alefacept Mechanism of Action in Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00150982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*